Evidence map›Paper›PMID 36689092›Full record

ArticleBreast cancer research and treatment2023

Outcomes and clinicopathologic characteristics associated with disseminated tumor cells in bone marrow after neoadjuvant chemotherapy in high-risk early stage breast cancer: the I-SPY SURMOUNT study.

Mark Jesus M Magbanua, Laura van 't Veer, Amy S Clark, A Jo Chien, Judy C Boughey, Hyo S Han, Anne Wallace, Heather Beckwith, Minetta C Liu, Christina Yau and 17 more

Registry-linked trialOpen access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Breast cancer research and treatment, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT01042379 (I-SPY Trial), which is not on this map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
1.6field-weighted citation impact, top 15% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT01042379 phase2recruitingnot on this map

I-SPY Trial (Investigation of Serial Studies to Predict Your Therapeutic Response With Imaging And moLecular Analysis 2)

TypeinterventionalSponsorQuantumLeap Healthcare CollaborativeRan2010 to 2031Enrolled5,000ConditionsBreast Neoplasms, Breast Cancer, Breast Tumors, AngiosarcomaArmsStandard Therapy, AMG 386 with or without Trastuzumab, AMG 479 (Ganitumab) plus Metformin, MK-2206 with or without Trastuzumab, AMG 386 and Trastuzumab
3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 7 citations in OpenAlex.

  1. Article
  2. Article
  3. Metastasis.Cell · 2023
    Review
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

27 authors at 6 institutions in 1 country.

Mark Jesus M MagbanuaUniversity of California San Francisco, San Francisco, CA, USA. mark.magbanua@ucsf.edu.ORCID http://orcid.org/0000-0003-2113-3593
Laura van 't VeerUniversity of California San Francisco, San Francisco, CA, USA.
Amy S ClarkUniversity of Pennsylvania, Philadelphia, PA, USA.
A Jo ChienUniversity of California San Francisco, San Francisco, CA, USA.
Judy C BougheyMayo Clinic, Rochester, MN, USA.
Hyo S HanMofitt Cancer Center, Tampa, FL, USA.
Anne WallaceUniversity of California San Diego, San Diego, CA, USA.
Heather BeckwithUniversity of Minnesota, Minneapolis, MN, USA.
Minetta C LiuMayo Clinic, Rochester, MN, USA.
Christina YauUniversity of California San Francisco, San Francisco, CA, USA.
E Paul WileytoUniversity of Pennsylvania, Philadelphia, PA, USA.
Andrea OrdonezUniversity of California San Francisco, San Francisco, CA, USA.
Tulasi I SolankiUniversity of California San Francisco, San Francisco, CA, USA.
Feng HsiaoUniversity of California San Francisco, San Francisco, CA, USA.
Jen Chieh LeeUniversity of California San Francisco, San Francisco, CA, USA.
Amrita BasuUniversity of California San Francisco, San Francisco, CA, USA.
Lamorna Brown SwigartUniversity of California San Francisco, San Francisco, CA, USA.
Jane PerlmutterUniversity of California San Francisco, San Francisco, CA, USA.
Amy L DelsonUniversity of California San Francisco, San Francisco, CA, USA.
Lauren BayneUniversity of Pennsylvania, Philadelphia, PA, USA.
Shannon DelucaUniversity of Pennsylvania, Philadelphia, PA, USA.
Stephanie S YeeUniversity of Pennsylvania, Philadelphia, PA, USA.
Erica L CarpenterUniversity of Pennsylvania, Philadelphia, PA, USA.
Laura J EssermanUniversity of California San Francisco, San Francisco, CA, USA.
John W ParkUniversity of California San Francisco, San Francisco, CA, USA.
Lewis A ChodoshUniversity of Pennsylvania, Philadelphia, PA, USA.
Angela DeMicheleUniversity of Pennsylvania, Philadelphia, PA, USA.
University of California, San Francisco · USUniversity of Pennsylvania · USMayo Clinic in Arizona · USMoffitt Cancer Center · USUniversity of California San Diego · USUniversity of Minnesota · US

Funding

Women's Cancer ProgramP30CA015083 · NCI · MAYO CLINIC ROCHESTER · PI Felicity Enders · 1985 to 2026
$151.3M
The Cancer Cell Map Initiative v2.0U54CA274502 · NCI · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI Trey Ideker, Nevan J Krogan · 2022 to 2026
$14.2M
Using Networks to Seed Hierarchical Whole-cell Models of CancerU54CA209891 · NCI · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI IDEKER, TREY · 2017 to 2021
$10.9M
Secondary Prevention through Surveillance and InterventionR01CA208273 · NCI · UNIVERSITY OF PENNSYLVANIA · PI CHODOSH, LEWIS A, DEMICHELE, ANGELA · 2017 to 2021
$3.2M
NCI NIH HHS P30 CA015083NCI NIH HHS R01 CA208273NCI NIH HHS U54 CA209891NCI NIH HHS U54 CA274502
6 · The paper itself

Abstract

purposeDisseminated tumor cells (DTCs) expressing epithelial markers in the bone marrow are associated with recurrence and death, but little is known about risk factors predicting their occurrence. We detected EPCAM+/CD45- cells in bone marrow from early stage breast cancer patients after neoadjuvant chemotherapy (NAC) in the I-SPY 2 Trial and examined clinicopathologic factors and outcomes.

methodsPatients who signed consent for SURMOUNT, a sub-study of the I-SPY 2 Trial (NCT01042379), had bone marrow collected after NAC at the time of surgery. EPCAM+CD45- cells in 4 mLs of bone marrow aspirate were enumerated using immunomagnetic enrichment/flow cytometry (IE/FC). Patients with > 4.16 EPCAM+CD45- cells per mL of bone marrow were classified as DTC-positive. Tumor response was assessed using the residual cancer burden (RCB), a standardized approach to quantitate the extent of residual invasive cancer present in the breast and the axillary lymph nodes after NAC. Association of DTC-positivity with clinicopathologic variables and survival was examined.

resultsA total of 73 patients were enrolled, 51 of whom had successful EPCAM+CD45- cell enumeration. Twenty-four of 51 (47.1%) were DTC-positive. The DTC-positivity rate was similar across receptor subtypes, but DTC-positive patients were significantly younger (p = 0.0239) and had larger pretreatment tumors compared to DTC-negative patients (p = 0.0319). Twenty of 51 (39.2%) achieved a pathologic complete response (pCR). While DTC-positivity was not associated with achieving pCR, it was significantly associated with higher RCB class (RCB-II/III, 62.5% vs. RCB-0/I; 33.3%; Chi-squared p = 0.0373). No significant correlation was observed between DTC-positivity and distant recurrence-free survival (p = 0.38, median follow-up = 3.2 years).

conclusionDTC-positivity at surgery after NAC was higher in younger patients, those with larger tumors, and those with residual disease at surgery.

Indexed as

Breast NeoplasmsBone MarrowEpithelial Cell Adhesion MoleculeFemaleFlow CytometryHumansNeoadjuvant TherapyPrognosisEpithelial Cell Adhesion MoleculeDisseminated tumor cellsNeoadjuvant chemotherapyPathologic complete responseResidual cancer burden

Identifiers

PMID36689092
PMCPMC10290540
OpenAlexW4317734496

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.